1. Son H, Byun SS, Park E, Cho KS, Jo MK, Kim SW, et al. Prevalence of sexual dysfunction in men older than 40 living in Seoul: epidemiologic survey using questionnaire. Korean J Urol. 2002. 43:52–61.
2. Cha JS, Park JK. Association between lower urinary tract symptoms and erectile dysfunction. Korean J Urol. 2005. 46:1023–1027.
3. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol. 1992. 148:1549–1557.
4. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008. 53:1236–1244.
5. Ahn TY, Lee DS, Kang W, Hong JH, Kim YS. Validation of an abridged Korean version of International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile function. Korean J Urol. 2001. 42:535–540.
6. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002. 14:226–244.
7. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peńa BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999. 11:319–326.
8. Cappelleri JC, Rosen RC. Reply to 'The sexual health inventory for men (IIEF-5)' by JA Vroege. Int J Impot Res. 1999. 11:353–354.
9. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003. 61:579–584.
10. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002. 90:836–839.
11. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003. 44:637–649.
12. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol. 1999. 161:635–640.
13. Zlotta AR, Schulman CC. BPH and sexuality. Eur Urol. 1999. 36(Suppl 1):107–112.
14. Schiff JD, Mulhall JP. The link between LUTS and ED: clinical and basic science evidence. J Androl. 2004. 25:470–478.
15. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep. 2004. 5:251–257.
16. Cho JJ, Cadet P, Salamon E, Mantione K, Stefano GB. The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men. Med Sci Monit. 2003. 9:RA63–RA68.
17. Frankel SJ, Donovan JL, Peters TI, Abrams P, Dabhoiwala NF, Osawa D, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 1998. 51:677–685.
18. Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, et al. Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology. 2004. 63:1148–1152.
19. Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology. 2004. 64:772–776.